Jérémie Calais, MD, PhD

Jérémie Calais, MD, PhD, is director of the theranostics and clinical research programs, Ahmanson Translational Theranostics Division, and associate professor, Department of Molecular and Medical Pharmacology, at the University of California, Los Angeles. He leads a clinical research program of nuclear medicine and theranostics combining radionuclide imaging and therapy.

Articles by Jérémie Calais, MD, PhD

Jérémie Calais, MD, PhDAdvanced Imaging | February 15, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
View More
Jérémie Calais, MD, PhDRLT | January 24, 2024
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Jérémie Calais, MD, PhDSNMMI 2023 | January 8, 2024
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Jérémie Calais, MD, PhDASCO 2023 | January 8, 2024
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
Johannes Czernin, MDRLT | January 8, 2024
Drs. Czernin and Calais explain how supply has become a large issue for Lutetium-177–PSMA-617 and strategies to overcome ...